Dr. Antonio Capone JR., MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- Warren Alpert Medical School of Brown University (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 403
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Warren Alpert Medical School of Brown University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
MI license 4301075697 -
Ophthalmology Physician
MI license 4301075697
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beaumont Hospital Royal Oak Royal Oak, MI
- Beaumont Hospital, Troy Troy, MI
Medical groups
- Associated Retinal Consultants PC (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 403
- Services billed
- 13,227
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 7,140 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,082 | 410 |
| Injection, aflibercept, 1 mg | 1,056 | 81 |
| Imaging of retina | 970 | 373 |
| Injection, ranibizumab, 0.1 mg | 900 | 41 |
| Injection of drug into eye | 697 | 150 |
| Photography of the retina | 271 | 193 |
| Extended exam of the back part of the eye with retinal drawing | 174 | 146 |
| Established patient office or other outpatient visit, 40-54 minutes | 73 | 49 |
| 2d ultrasound scan of eye tissue and structures | 72 | 61 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Royal Oak, MI | 28 |
| Latanoprost Other prescribers in Royal Oak, MI | 25 |
| Difluprednate | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 12 payments worth $930 in total to this clinician.
| Genentech USA, Inc. | $347 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $194 |
| Astellas Pharma US Inc | $190 |
| Astellas Pharma Global Development | $107 |
| AbbVie Inc. | $71.66 |
| Ani Pharmaceuticals, Inc. | $20.98 |
| Food and Beverage | $930 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $25,061 in research payments for these studies, mostly to the institutions running them.
- Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - A phase 2, multicenter, randomized, double-masked, parallel group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related m…
Kyowa Kirin, Inc. - NRICH
Notal Vision, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.